{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055062","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.340958+00:00","generated_at":"2026-06-02T12:31:48.794187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tango Therapeutics Q1 2024 net loss $37.9M ($0.35/sh); cash $343.6M funds into late 2026","bullets":["Net loss of $37.9M, or $0.35 per share, vs $28.0M ($0.32) in Q1 2023.","Cash, equivalents and marketable securities of $343.6M as of March 31, 2024.","R&D expense rose to $38.1M from $28.0M due to clinical program advancement.","Dose expansion initiated for TNG908 (PRMT5 inhibitor) in MTAP-deleted tumors.","PRMT5 clinical data update expected in 2H 2024; TNG462 expansion expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055062","json":"https://secwatch.observer/filing/0000950170-24-055062.json","markdown":"https://secwatch.observer/filing/0000950170-24-055062.md","text":"https://secwatch.observer/filing/0000950170-24-055062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024055062/0000950170-24-055062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024055062/tngx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:31:48.794187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"441b2872dd01efc1edd9fe8989cbcdb23fc044b6","claim":"Tango Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.5 million, net income $37.9 million, EPS $0.35 per share.","evidence_excerpt":"held $343.6 million in cash, cash equivalents and marketable securities, which the Company expects to be sufficient to fund operations into late 2026. Collaboration revenue was $6.5 million for the three months ended March 31, 2024, compared to $5.8 million for the same period in 2023. Research costs incurred under the collaboration were similar during each of the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024055062/0000950170-24-055062-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$6.5 million"},{"label":"Net income","value":"$37.9 million"},{"label":"EPS","value":"$0.35 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}